C WorldWide Group’s Vertex Pharmaceuticals VRTX Stock Holding History

C WorldWide Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.9M	Hold	46,057	–	–	0.55%	29
2026 Q1	$20.6M	Hold	46,057	–	–	0.44%	31
2025 Q4	$20.9M	Hold	46,057	–	–	0.36%	38
2025 Q3	$18M	Hold	46,057	–	–	0.28%	39
2025 Q2	$20.5M	Sell	46,057 -8,000	-15%	-$3.69M	0.28%	36
2025 Q1	$26.2M	Sell	54,057 -13,500	-20%	-$6.29M	0.33%	30
2024 Q4	$27.2M	Hold	67,557	–	–	0.33%	29
2024 Q3	$31.4M	Sell	67,557 -4,000	-6%	-$1.92M	0.33%	44
2024 Q2	$33.5M	Hold	71,557	–	–	0.36%	44
2024 Q1	$29.9M	Hold	71,557	–	–	0.34%	42
2023 Q4	$29.1M	Sell	71,557 -22,000	-24%	-$8.13M	0.39%	27
2023 Q3	$32.5M	Hold	93,557	–	–	0.44%	25
2023 Q2	$32.9M	Hold	93,557	–	–	0.43%	24
2023 Q1	$29.5M	Hold	93,557	–	–	0.4%	27
2022 Q4	$27M	Hold	93,557	–	–	0.36%	26
2022 Q3	$27.1M	Sell	93,557 -15,000	-14%	-$4.32M	0.37%	22
2022 Q2	$30.6M	Hold	108,557	–	–	0.38%	22
2022 Q1	$28.3M	Hold	108,557	–	–	0.31%	25
2021 Q4	$23.8M	Hold	108,557	–	–	0.23%	30
2021 Q3	$19.7M	Hold	108,557	–	–	0.2%	33
2021 Q2	$21.9M	Hold	108,557	–	–	0.23%	32
2021 Q1	$23.3M	Buy	108,557 +20,000	+23%	+$4.39M	0.23%	36
2020 Q4	$20.9M	Buy	88,557 +20,000	+29%	+$4.59M	0.21%	39
2020 Q3	$18.7M	Hold	68,557	–	–	0.21%	39
2020 Q2	$19.9M	Hold	68,557	–	–	0.23%	37
2020 Q1	$16.3M	Hold	68,557	–	–	0.23%	33
2019 Q4	$15M	Hold	68,557	–	–	0.18%	39
2019 Q3	$11.6M	Hold	68,557	–	–	0.15%	41
2019 Q2	$12.6M	Hold	68,557	–	–	0.16%	48
2019 Q1	$12.6M	Sell	68,557 -4,780	-7%	-$883K	0.16%	34
2018 Q4	$12.2M	Sell	73,337 -2,006	-3%	-$348K	0.18%	32
2018 Q3	$14.5M	Buy	75,343 +10,813	+17%	+$1.93M	0.19%	31
2018 Q2	$11M	Buy	64,530 +16,134	+33%	+$2.5M	0.15%	39
2018 Q1	$7.89M	Sell	48,396 -192	-0.4%	-$31.4K	0.12%	46
2017 Q4	$7.28M	Buy	48,588 +10,442	+27%	+$1.55M	0.11%	51
2017 Q3	$5.8M	Buy	38,146 +32,146	+536%	+$4.84M	0.08%	58
2017 Q2	$773K	Sell	6,000 -818	-12%	-$98.5K	0.01%	111
2017 Q1	$746K	Buy	6,818 +812	+14%	+$71.5K	0.01%	107
2016 Q4	$442K	Sell	6,006 -14,794	-71%	-$1.2M	0.01%	109
2016 Q3	$1.81M	Buy	20,800 +1,500	+8%	+$142K	0.03%	94
2016 Q2	$1.66M	Hold	19,300	–	–	0.03%	78
2016 Q1	$1.53M	Sell	19,300 -2,200	-10%	-$199K	0.03%	84
2015 Q4	$2.71M	Sell	21,500 -1,600	-7%	-$193K	0.05%	73
2015 Q3	$2.41M	Buy	23,100 +450	+2%	+$57.8K	0.04%	81
2015 Q2	$2.8M	Buy	22,650 +1,250	+6%	+$158K	0.04%	83
2015 Q1	$2.52M	Sell	21,400 -500	-2%	-$59.9K	0.04%	77
2014 Q4	$2.6M	Sell	21,900 -2,500	-10%	-$282K	0.04%	68
2014 Q3	$2.75M	Buy	+24,400	New	+$2.32M	0.04%	69

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

C WorldWide Group's VRTX Position: Q2 2026 in Review

C WorldWide Group held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 46,057 shares worth $22.9M. The position accounts for 0.55% of the portfolio, ranked #29.

C WorldWide Group first reported a position in VRTX in Q3 2014 and has held it in 48 quarters since. The position peaked at $33.5M in Q2 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

C WorldWide Group held 46,057 shares of Vertex Pharmaceuticals worth $22.9M as of Q2 2026.
C WorldWide Group left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.55% of C WorldWide Group's portfolio in Q2 2026, its #29 holding.
C WorldWide Group first reported a position in Vertex Pharmaceuticals in Q3 2014 and has held it in 48 quarters since.
C WorldWide Group's Vertex Pharmaceuticals position peaked at $33.5M in Q2 2024.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on C WorldWide Group's 13F filing for Q2 2026, filed 4 Aug 2026.